- Home
- MSPR vs DRMA Comparison
MSPR vs DRMA Comparison
Compare MSPR & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSPR
- DRMA
- Stock Information
- Founded
- MSPR 2014
- DRMA 2014
- Country
- MSPR United States
- DRMA United States
- Employees
- MSPR N/A
- DRMA N/A
- Industry
- MSPR
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- MSPR
- DRMA Health Care
- Exchange
- MSPR NYSE
- DRMA Nasdaq
- Market Cap
- MSPR 5.3M
- DRMA 4.5M
- IPO Year
- MSPR N/A
- DRMA 2021
- Fundamental
- Price
- MSPR $0.98
- DRMA $0.70
- Analyst Decision
- MSPR
- DRMA Strong Buy
- Analyst Count
- MSPR 0
- DRMA 1
- Target Price
- MSPR N/A
- DRMA $3.00
- AVG Volume (30 Days)
- MSPR 914.9K
- DRMA 162.6K
- Earning Date
- MSPR 08-13-2025
- DRMA 08-06-2025
- Dividend Yield
- MSPR N/A
- DRMA N/A
- EPS Growth
- MSPR N/A
- DRMA N/A
- EPS
- MSPR N/A
- DRMA N/A
- Revenue
- MSPR $13,085,000.00
- DRMA N/A
- Revenue This Year
- MSPR N/A
- DRMA N/A
- Revenue Next Year
- MSPR N/A
- DRMA N/A
- P/E Ratio
- MSPR N/A
- DRMA N/A
- Revenue Growth
- MSPR 34.74
- DRMA N/A
- 52 Week Low
- MSPR $0.87
- DRMA $0.57
- 52 Week High
- MSPR $11.20
- DRMA $3.79
- Technical
- Relative Strength Index (RSI)
- MSPR N/A
- DRMA 51.04
- Support Level
- MSPR N/A
- DRMA $0.64
- Resistance Level
- MSPR N/A
- DRMA $0.75
- Average True Range (ATR)
- MSPR 0.00
- DRMA 0.07
- MACD
- MSPR 0.00
- DRMA 0.01
- Stochastic Oscillator
- MSPR 0.00
- DRMA 46.10
About MSPR MSP RECOVERY INC
MSP Recovery Inc is a healthcare recovery and data analytics company. The business model includes two principal lines of business: Claims Recovery and Chase to Pay Services. It offers an antiquated healthcare reimbursement system with data-driven solutions to secure recoveries against responsible parties. MSP Recovery provides the healthcare industry with comprehensive compliance solutions platform to recover any claims where the law places primary payment responsibility on another payer.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.